UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 4)*

tronc, Inc.
(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

89703P107
(CUSIP Number)

California Capital Equity, LLC

Attn: Patrick Soon-Shiong
9920 Jefferson Boulevard
Culver City, California 90232
(310) 836-6400

With a Copy to:

Martin J. Waters
Daniel L. Horwood
Wilson Sonsini Goodrich & Rosati
Professional Corporation
12235 El Camino Real, Suite 200
San Diego, California 92130
(858) 350-2300
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 5, 2017
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other
parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a Reporting Persons initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act
of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 89703P107 13D/A
(1) NAMES OF REPORTING PERSONS

California Capital Equity, LLC

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a) (b)
(3) SEC USE ONLY

(4) SOURCE OF FUNDS (see instructions)

WC, AF (See Item 3)

(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e)

(6) CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
(7) SOLE VOTING POWER

NUMBER OF None (See Item 5)

SHARES (8) SHARED VOTING POWER
BENEFICIALLY
OWNED BY
7,650,000 shares (See Item 5)
EACH
REPORTING (9) SOLE DISPOSITIVE POWER
PERSON
WITH None (See Item 5)
(10) SHARED DISPOSITIVE POWER

7,650,000 shares (See Item 5)

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,650,000 shares (See Item 5)

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

23.4% (See Item 5)

(14) TYPE OF REPORTING PERSON (see instructions)

OO

Page 2 of 7
CUSIP No. 89703P107 13D/A
(1) NAMES OF REPORTING PERSONS

Nant Capital, LLC

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a) (b)
(3) SEC USE ONLY

(4) SOURCE OF FUNDS (see instructions)

WC, AF (See Item 3)

(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e)

(6) CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
(7) SOLE VOTING POWER

NUMBER OF None (See Item 5)

SHARES (8) SHARED VOTING POWER
BENEFICIALLY
OWNED BY
7,650,000 shares (See Item 5)
EACH
REPORTING (9) SOLE DISPOSITIVE POWER
PERSON
WITH None (See Item 5)
(10) SHARED DISPOSITIVE POWER

7,650,000 shares (See Item 5)

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,650,000 shares (See Item 5)

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

23.4% (See Item 5)

(14) TYPE OF REPORTING PERSON (see instructions)

OO

Page 3 of 7
CUSIP No. 89703P107 13D/A
(1) NAMES OF REPORTING PERSONS

Patrick Soon-Shiong
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a) (b)
(3) SEC USE ONLY

(4) SOURCE OF FUNDS (see instructions)

WC, AF (See Item 3)

(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e)

(6) CITIZENSHIP OR PLACE OF ORGANIZATION

United States
(7) SOLE VOTING POWER

NUMBER OF 1,093,619 (See Item 5)

SHARES (8) SHARED VOTING POWER
BENEFICIALLY
OWNED BY
8,743,619 shares (See Item 5)
EACH
REPORTING (9) SOLE DISPOSITIVE POWER
PERSON
WITH 1,093,619 shares (See Item 5)
(10) SHARED DISPOSITIVE POWER

8,743,619 shares (See Item 5)

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,743,619 shares (See Item 5)

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

26.7% (See Item 5)

(14) TYPE OF REPORTING PERSON (see instructions)

PN

Page 4 of 7
 This Amendment No.4 amends and supplements the Schedule 13D (as amended, this Schedule 13D) filed with the Securities and Exchange
Commission (the SEC) on June 7, 2016, as amended by amendment no. 1 to Schedule 13D filed with the SEC on November 23, 2016, amendment no. 2 to
Schedule 13D filed with the SEC on March 22, 2017 and amendment no. 3 to Schedule 13D filed with the SEC on March 28, 2017 by certain of the
Reporting Persons (as defined below) with respect to the common stock, par value $0.01 per share (Common Stock) of tronc, Inc., a Delaware corporation
(formerly known as Tribune Publishing Company, the Issuer) by Dr. Patrick Soon-Shiong, a natural person and citizen of the United States, Nant Capital,
LLC, limited liability company organized under the laws of the state of Delaware (Nant Capital) and California Capital Equity, LLC, a limited liability
company organized under the laws of the state of Delaware (CalCap and, together with Dr. Soon-Shiong, and Nant Capital, the Reporting Persons).

Except as otherwise set forth below, the information set forth in the Schedule 13D remains unchanged and is incorporated by reference into this
Amendment.

Percentages are based upon a total of 32,695,496 shares outstanding, based on the information contained in the Issuers Annual Report on Form 10-K
filed on March 9, 2017 and the Current Report on Form 8-K filed on March 23, 2017.

Item 4. Purpose of Transaction.

Item 4 of this Schedule 13D is hereby amended and restated as follows:
On April 5, 2017, counsel for the Reporting Persons delivered the letter attached as Exhibit 6 hereto (the Nant Letter) to Yosef J. Riemer, counsel for
the Issuer, in response to a letter received by Mr. Riemer on March 28, 2017 (the tronc Letter). The Nant Letter outlines the Reporting Persons reasons why
they believe that the Issuers Chairman should not receive preferential treatment over the Reporting Persons or any other shareholder, and includes specific
examples of what the Reporting Persons believe are misstatements and fabrications made by the Issuer and its counsel in the tronc Letter, as well as specific
examples of poor corporate governance by tronc.

In addition, as previously disclosed in the Schedule 13D filed by the Reporting Persons on June 8, 2016, NantWorks, LLC (NantWorks), an affiliate
of the Reporting Persons, was finalizing terms with the Issuer for a co-exclusive, non-transferable, fee-bearing license pursuant to which the Issuer will receive
access to over 100 machine vision and artificial intelligence technology patents for news media applications as well as access to and use of studio space
made available by NantStudio, LLC, a subsidiary of NantWorks. While a more definitive agreement has not yet been finalized, NantWorks and the Issuer
entered into a Binding Term Sheet on May 22, 2016 (the Binding Term Sheet), which provides that if the parties do not execute a more definitive
agreement within a reasonable time, then the Binding Term Sheet will be enforceable against both parties, but is contingent upon Tribune Media approval. In
connection with these transactions, the Company will issue to NantStudio, LLC 333,333 shares of Common Stock, which shares will be beneficially owned
by the Reporting Persons.

Except as set forth herein, the Reporting Persons do not currently have any specific plan or proposal with respect to any action that would result in the
occurrence of any of the matters specified in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to change their
purpose and to formulate and implement plans or proposals with respect to the Issuer at any time and from time to time, including, but not limited to,
purchasing or otherwise acquiring additional securities of the Issuer (subject to any contractual or other limitations that may current exist), selling or
otherwise disposing of any securities of the Issuer beneficially owned by the Reporting Persons, in each case in the open market or in privately negotiated
transactions or formulating other plans or proposals regarding the Issuer or its securities to the extent deemed advisable by the Reporting Persons in light of,
among other things, the investment strategy of the Reporting Persons, market conditions, subsequent developments affecting the Issuer and the general
business and future prospects of the Issuer.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

The following document is filed as an exhibit to this Schedule 13D:
Exhibit 6: Letter from John B. Quinn to the Issuer, dated April 5, 2017.

Page 5 of 7
 SIGNATURE

After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the information set forth in this statement is true, complete and
correct.

Dated: April 5, 2017

NANT CAPITAL, LLC

By: /s/ Charles Kenworthy

Its: Manager

CALIFORNIA CAPITAL EQUITY, LLC

By: /s/ Charles Kenworthy

Its: Manager

PATRICK SOON-SHIONG

/s/ Patrick Soon-Shiong

Page 6 of 7
 Exhibit Index

Exhibit
Number Description
1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Schedule 13D filed on June 7, 2016).
2 Securities Purchase Agreement, by and among Tribune Publishing Company, Nant Capital, LLC and Dr. Patrick Soon-Shiong, dated as of
May 22, 2016 (incorporated by reference to Exhibit 10.1 to the Issuers Current Report on Form 8-K (File No. 001- 36230) filed with the
SEC on May 23, 2016).
3 Registration Rights Agreement, by and between Tribune Publishing Company and Nant Capital, LLC, dated as of May 22, 2016
(incorporated by reference to Exhibit 10.1 to the Issuers Current Report on Form 8-K (File No. 001- 36230) filed with the SEC on May 23,
2016).
4 Stock Purchase Agreement, dated as of February 24, 2017, by and between HG Vora Special Opportunities Master Fund, Ltd. and Nant
Capital, LLC (incorporated by reference to Exhibit 4 to the Schedule 13D/A filed on March 22, 2017).
5 Letter from John B. Quinn to the Issuer, dated March 27, 2017 (incorporated by reference to Exhibit 5 to the Schedule 13D/A filed on
Mach 28, 2017).
6 Letter from John B. Quinn to Yosef J. Reimer, Counsel to the Issuer, dated April 5, 2017.

Page 7 of 7
 Exhibit 6

April 5, 2017

Via E-mail

yriemer@kirkland.com
Yosef J. Riemer
Kirkland & Ellis LLP
601 Lexington Avenue
New York, New York 10022

Dear Mr. Riemer:

I am writing in further response to your letter dated March 28, 2017, which responded to my
March 27, 2017 demand letter. With all due respect, the assertions in your letter appear to be more of the same: revisionist history designed to divert attention
from the poor corporate governance of the tronc Board.

The implication that Merrick as a shareholder should receive preferential treatment over Nant or any other shareholder because Merricks agreement requires
that Merrick vote its shares in favor of all Board-recommended mattersincluding the re-election of incumbent directorswhile Dr. Soon-Shiong and other
shareholders may vote their shares as they wish (including against the re-election of poorly-performing directors) not only is preposterous, but also is yet
another example of troncs directors seeking to justify a corporate governance structure that plainly is designed to entrench their Board seats. Sadly, this is
just the latest example of appalling corporate governance by a Board that has, over Dr. Soon-Shiongs objections, repeatedly approved Mr. Ferros personal
requests, including a $2.7 million reimbursement for use of his private aircraft, the purchase by tronc of a reported $250,000 of sports tickets from Mr. Ferros
Merrick Capital, and the leasing by tronc of real estate from a Mr. Ferro-affiliated companyall while the company is struggling to turn itself around and
having to lay off much needed valuable newsroom staff.

As yet another example of disregard of corporate governance, just a few weeks ago Dr. Soon- Shiong received a personal telephone call from Mr. Ferro
requesting that Dr. Soon-Shiong go along with a proposal by which Mr. Ferro would get the tronc Board to agree to buy Mr. Ferros personal NantHealth
shares back at the IPO price and in turn would agree (and would get the Board to agree) to comply with troncs agreement to award Nant 300,000 tronc shares
in consideration for a license to the machine vision technology as contemplated in the binding term sheet. Mr. Ferro asserted that he had already obtained
preliminary Board approval for this proposal. Dr. Soon-Shiong informed Mr. Ferro that this proposal was improper and that he wanted nothing to do with the
concept.

Furthermore, at the recent HIMSS conference, Dr. Soon-Shiong received yet another unsolicited call from Mr. Ferro inquiring as to how he could personally
invest in Dr. Soon-Shiongs health companies, and thereafter Mr. Ferro attended Dr. Soon-Shiongs keynote address at the HIMSS conference held in Florida.
Your letter mentions that Dr. Soon-Shiong has missed Board meetings. Aside from the fact that in more than one instance Dr. Soon-Shiong was given the
wrong call-in number and, by the time he was able to get the right call-in number the meeting was near adjournment or was being adjourned, meetings were
scheduled in the middle of the night in the time zone where Dr. Soon- Shiong was while traveling and, at times, at 5:00 a.m. California time when he was not.

As I stated in a prior letter, when Dr. Soon-Shiong was informed at the December 23, 2016 meeting that the Board was allowing only Mr. Ferro to purchase
shares during a blackout period, Dr. Soon-Shiong demanded and the Board approved that all Directors be treated equally.

Regarding the annual meeting, troncs directors moved the date up with no advance notice and with no corporate purpose other than to curtail the right of
shareholders to nominate directors and thereby to secure the re-election of the Boards nominees.

With respect to your assertion that conditions to payment for the technology agreement between tronc and Nant were not met and tronc does not have an
obligation to pay Nant the consideration laid out in the agreement, this assertion too is incorrect.

Finally, it is a complete fabrication to say that before investing in tronc or beginning his service on the Board of tronc, Dr. Soon-Shiong requested that tronc,
Merrick, or Mr. Ferro invest in the IPO of NantHealth. It is also patently untrue that Dr. Soon-Shiong made an implicit threat or any other kind of threat that,
if Merrick did not invest in NantHealth, he would not invest in tronc. There was never any such issue raised with Merrick, tronc, Mr. Ferro, or anyone else
associated with tronc. Whats more, Dr. Soon-Shiong signed the agreement for the equity investment in tronc on May 22, before NantHealth even began its
IPO roadshow, and nowhere in the stock purchase agreement is there any obligation for tronc, Mr. Ferro, or Merrick to invest in the NantHealth IPO. What
makes these statements even more preposterous is that NantHealth did not need such an investment. Its IPO was oversubscribed.

As before, we reserve all available rights and remedies available at law or in equity in connection with the foregoing.

Very truly yours,

/s/ John B. Quinn

John B. Quinn
JBQ/wpc

cc: Julie K. Xanders, Esq.

Justin Dearborn, Esq.
Terry Jimenez
Rebecca Kwok Marquez, Esq.
Charles Kim, Esq.
Charles Kenworthy, Esq.

-2-